Literature DB >> 36268097

Immunohistochemistry scoring of breast tumor tissue microarrays: A comparison study across three software applications.

Gabrielle M Baker1, Vanessa C Bret-Mounet1, Tengteng Wang2,3, Mitko Veta4, Hanqiao Zheng1, Laura C Collins1, A Heather Eliassen2,3, Rulla M Tamimi5, Yujing J Heng1.   

Abstract

Digital pathology can efficiently assess immunohistochemistry (IHC) data on tissue microarrays (TMAs). Yet, it remains important to evaluate the comparability of the data acquired by different software applications and validate it against pathologist manual interpretation. In this study, we compared the IHC quantification of 5 clinical breast cancer biomarkers-estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin 5/6 (CK5/6)-across 3 software applications (Definiens Tissue Studio, inForm, and QuPath) and benchmarked the results to pathologist manual scores. IHC expression for each marker was evaluated across 4 TMAs consisting of 935 breast tumor tissue cores from 367 women within the Nurses' Health Studies; each women contributing three 0.6-mm cores. The correlation and agreement between manual and software-derived results were primarily assessed using Spearman's ρ, percentage agreement, and area under the curve (AUC). At the TMA core-level, the correlations between manual and software-derived scores were the highest for HER2 (ρ ranging from 0.75 to 0.79), followed by ER (0.69-0.71), PR (0.67-0.72), CK5/6 (0.43-0.47), and EGFR (0.38-0.45). At the case-level, there were good correlations between manual and software-derived scores for all 5 markers (ρ ranging from 0.43 to 0.82), where QuPath had the highest correlations. Software-derived scores were highly comparable to each other (ρ ranging from 0.80 to 0.99). The average percentage agreements between manual and software-derived scores were excellent for ER (90.8%-94.5%) and PR (78.2%-85.2%), moderate for HER2 (65.4%-77.0%), highly variable for EGFR (48.2%-82.8%), and poor for CK5/6 (22.4%-45.0%). All AUCs across markers and software applications were ≥0.83. The 3 software applications were highly comparable to each other and to manual scores in quantifying these 5 markers. QuPath consistently produced the best performance, indicating this open-source software is an excellent alternative for future use.
© 2022 The Authors.

Entities:  

Keywords:  Automation; Cytokeratin 5/6; Definiens; Epithelium growth factor receptor; Estrogen receptor; Progesterone receptor; QuPath; inForm

Year:  2022        PMID: 36268097      PMCID: PMC9577037          DOI: 10.1016/j.jpi.2022.100118

Source DB:  PubMed          Journal:  J Pathol Inform


  31 in total

1.  Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer.

Authors:  Rulla M Tamimi; Graham A Colditz; Yihong Wang; Laura C Collins; Rong Hu; Bernard Rosner; Hanna Y Irie; James L Connolly; Stuart J Schnitt
Journal:  Breast Cancer Res Treat       Date:  2011-01-01       Impact factor: 4.872

Review 2.  The Gold Standard Paradox in Digital Image Analysis: Manual Versus Automated Scoring as Ground Truth.

Authors:  Famke Aeffner; Kristin Wilson; Nathan T Martin; Joshua C Black; Cris L Luengo Hendriks; Brad Bolon; Daniel G Rudmann; Roberto Gianani; Sally R Koegler; Joseph Krueger; G Dave Young
Journal:  Arch Pathol Lab Med       Date:  2017-05-30       Impact factor: 5.534

3.  The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study.

Authors:  Ying Liu; Rulla M Tamimi; Laura C Collins; Stuart J Schnitt; Hannah L Gilmore; James L Connolly; Graham A Colditz
Journal:  Breast Cancer Res Treat       Date:  2011-03-09       Impact factor: 4.872

4.  Alcohol Consumption and Risk of Breast Cancer by Tumor Receptor Expression.

Authors:  Jun Wang; Xuehong Zhang; Andrew H Beck; Laura C Collins; Wendy Y Chen; Rulla M Tamimi; Aditi Hazra; Myles Brown; Bernard Rosner; Susan E Hankinson
Journal:  Horm Cancer       Date:  2015-09-18       Impact factor: 3.869

5.  Alcohol consumption and risk of breast cancer by molecular subtype: Prospective analysis of the nurses' health study after 26 years of follow-up.

Authors:  Kelly A Hirko; Wendy Y Chen; Walter C Willett; Bernard A Rosner; Susan E Hankinson; Andrew H Beck; Rulla M Tamimi; A Heather Eliassen
Journal:  Int J Cancer       Date:  2015-10-05       Impact factor: 7.396

6.  The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women.

Authors:  Sung Jin Huh; Hannah Oh; Michael A Peterson; Vanessa Almendro; Rong Hu; Michaela Bowden; Rosina L Lis; Maura B Cotter; Massimo Loda; William T Barry; Kornelia Polyak; Rulla M Tamimi
Journal:  Cancer Res       Date:  2016-03-03       Impact factor: 12.701

7.  Potential role of tissue microarrays for the study of biomarker expression in benign breast disease and normal breast tissue.

Authors:  Laura C Collins; Yihong Wang; James L Connolly; Heather J Baer; Rong Hu; Stuart J Schnitt; Graham A Colditz; Rulla M Tamimi
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-10

8.  Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.

Authors:  Mustapha Abubakar; Jenny Chang-Claude; H Raza Ali; Nilanjan Chatterjee; Penny Coulson; Frances Daley; Fiona Blows; Javier Benitez; Roger L Milne; Hermann Brenner; Christa Stegmaier; Arto Mannermaa; Anja Rudolph; Peter Sinn; Fergus J Couch; Peter Devilee; Rob A E M Tollenaar; Caroline Seynaeve; Jonine Figueroa; Jolanta Lissowska; Stephen Hewitt; Maartje J Hooning; Antoinette Hollestelle; Renée Foekens; Linetta B Koppert; Manjeet K Bolla; Qin Wang; Michael E Jones; Minouk J Schoemaker; Renske Keeman; Douglas F Easton; Anthony J Swerdlow; Mark E Sherman; Marjanka K Schmidt; Paul D Pharoah; Montserrat Garcia-Closas
Journal:  Int J Cancer       Date:  2018-03-25       Impact factor: 7.396

9.  Reliability of a computational platform as a surrogate for manually interpreted immunohistochemical markers in breast tumor tissue microarrays.

Authors:  Michelle R Roberts; Gabrielle M Baker; Yujing J Heng; Michael E Pyle; Kristina Astone; Bernard A Rosner; Laura C Collins; A Heather Eliassen; Rulla M Tamimi
Journal:  Cancer Epidemiol       Date:  2021-08-02       Impact factor: 2.890

10.  Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.

Authors:  Rulla M Tamimi; Heather J Baer; Jonathan Marotti; Mark Galan; Laurie Galaburda; Yineng Fu; Anne C Deitz; James L Connolly; Stuart J Schnitt; Graham A Colditz; Laura C Collins
Journal:  Breast Cancer Res       Date:  2008-08-05       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.